drug

CTX310

1 story · latest Aug 3, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by CRISPR Therapeutics AG

Timeline

CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial starts

Aug 3Quarterly updateCRISPR Therapeutics AG CTX340

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.